Kiromic BioPharma, Inc. (NASDAQ:KRBP – Get Rating) – Equities research analysts at Diamond Equity issued their Q1 2023 EPS estimates for Kiromic BioPharma in a research note issued to investors on Thursday, May 19th. Diamond Equity analyst H. Diamond forecasts that the company will post earnings of ($0.43) per share for the quarter. Diamond Equity also issued estimates for Kiromic BioPharma’s Q2 2023 earnings at ($0.45) EPS, Q3 2023 earnings at ($0.47) EPS, Q4 2023 earnings at ($0.50) EPS, FY2023 earnings at ($1.85) EPS and FY2024 earnings at ($1.99) EPS.
A number of hedge funds and other institutional investors have recently bought and sold shares of KRBP. 1492 Capital Management LLC grew its stake in Kiromic BioPharma by 21.3% during the 3rd quarter. 1492 Capital Management LLC now owns 434,408 shares of the company’s stock valued at $1,334,000 after acquiring an additional 76,402 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Kiromic BioPharma during the 1st quarter valued at about $48,000. LPL Financial LLC purchased a new position in Kiromic BioPharma during the 3rd quarter valued at about $162,000. Geode Capital Management LLC purchased a new position in Kiromic BioPharma during the 3rd quarter valued at about $158,000. Finally, Warberg Asset Management LLC grew its stake in Kiromic BioPharma by 118.4% during the 1st quarter. Warberg Asset Management LLC now owns 73,847 shares of the company’s stock valued at $63,000 after acquiring an additional 40,032 shares in the last quarter. Hedge funds and other institutional investors own 16.03% of the company’s stock.
Kiromic BioPharma Company Profile (Get Rating)
Kiromic BioPharma, Inc, a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy.
- Get a free copy of the StockNews.com research report on Kiromic BioPharma (KRBP)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Kiromic BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiromic BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.